This modification shields YAP from proteasomal degradation by recruiting the deubiquitinase Eukaryotic Translation Initiation Factor 3 Subunit H (EIF3H), leading to YAP stabilization, tumor growth, and diminished chemotherapy effectiveness. This evidence concerns the gene YAP1 and neoplasm.